Current Status of Vaccines for Schistosomiasis

Overview

Journal Clin Microbiol Rev

Publisher American Society for Microbiology

Specialty Microbiology

Date 2008 Jan 19

PMID 18202444

Citations 197

Authors

Donald P McManus

Alex Loukas

Affiliations

Soon will be listed here.

Abstract

Schistosomiasis, caused by trematode blood flukes of the genus Schistosoma, is recognized as the most important human helminth infection in terms of morbidity and mortality. Infection follows direct contact with freshwater harboring free-swimming larval (cercaria) forms of the parasite. Despite the existence of the highly effective antischistosome drug praziquantel (PZQ), schistosomiasis is spreading into new areas, and although it is the cornerstone of current control programs, PZQ chemotherapy does have limitations. In particular, mass treatment does not prevent reinfection. Furthermore, there is increasing concern about the development of parasite resistance to PZQ. Consequently, vaccine strategies represent an essential component for the future control of schistosomiasis as an adjunct to chemotherapy. An improved understanding of the immune response to schistosome infection, both in animal models and in humans, suggests that development of a vaccine may be possible. This review considers aspects of antischistosome protective immunity that are important in the context of vaccine development. The current status in the development of vaccines against the African (Schistosoma mansoni and S. haematobium) and Asian (S. japonicum) schistosomes is then discussed, as are new approaches that may improve the efficacy of available vaccines and aid in the identification of new targets for immune attack.

Citing Articles

Revisiting immunity vs. exposure in schistosomiasis: A mathematical modeling study of delayed concomitant immunity.

Milne G, Oettle R, Whittaker C, Kabatereine N, Basanez M, Webster J PNAS Nexus. 2024; 3(10):pgae471.

PMID: 39474500 PMC: 11521328. DOI: 10.1093/pnasnexus/pgae471.

The efficacy of cercarial antigen loaded on nanoparticles as a potential vaccine candidate in -infected mice.

Elguindy D, Ashour D, Elmarhoumy S, El-Guindy D, Ismail H J Parasit Dis. 2024; 48(2):381-399.

PMID: 38840868 PMC: 11147980. DOI: 10.1007/s12639-024-01677-z.

Transmission-Blocking Vaccines against Schistosomiasis Japonica.

Zumuk C, Jones M, Navarro S, Gray D, You H Int J Mol Sci. 2024; 25(3).

PMID: 38338980 PMC: 10855202. DOI: 10.3390/ijms25031707.

Anti-schistosomal immunity to core xylose/fucose in N-glycans.

Prasanphanich N, Leon K, Evan Secor W, Shoemaker C, Heimburg-Molinaro J, Cummings R Front Mol Biosci. 2023; 10:1142620.

PMID: 37081851 PMC: 10110957. DOI: 10.3389/fmolb.2023.1142620.

A randomized, controlled Phase 1b trial of the Sm-TSP-2 Vaccine for intestinal schistosomiasis in healthy Brazilian adults living in an endemic area.

Diemert D, Correa-Oliveira R, Fraga C, Talles F, Silva M, Patel S PLoS Negl Trop Dis. 2023; 17(3):e0011236.

PMID: 36996185 PMC: 10089325. DOI: 10.1371/journal.pntd.0011236.

References

Wilson R, Ashton P, Braschi S, Dillon G, Berriman M, Ivens A . 'Oming in on schistosomes: prospects and limitations for post-genomics. Trends Parasitol. 2006; 23(1):14-20. DOI: 10.1016/j.pt.2006.10.002. View

Diallo T, Remoue F, Schacht A, Charrier N, Dompnier J, Pillet S . Schistosomiasis co-infection in humans influences inflammatory markers in uncomplicated Plasmodium falciparum malaria. Parasite Immunol. 2005; 26(8-9):365-9. DOI: 10.1111/j.0141-9838.2004.00719.x. View

Mei H, LoVerde P . Schistosoma mansoni: the developmental regulation and immunolocalization of antioxidant enzymes. Exp Parasitol. 1997; 86(1):69-78. DOI: 10.1006/expr.1997.4150. View

Fonseca C, Brito C, Alves J, Oliveira S . IL-12 enhances protective immunity in mice engendered by immunization with recombinant 14 kDa Schistosoma mansoni fatty acid-binding protein through an IFN-gamma and TNF-alpha dependent pathway. Vaccine. 2003; 22(3-4):503-10. DOI: 10.1016/j.vaccine.2003.07.010. View

Mutapi F, Burchmore R, Mduluza T, Foucher A, Harcus Y, Nicoll G . Praziquantel treatment of individuals exposed to Schistosoma haematobium enhances serological recognition of defined parasite antigens. J Infect Dis. 2005; 192(6):1108-18. DOI: 10.1086/432553. View

Bickle Q, Bogh H, Johansen M, Zhang Y . Comparison of the vaccine efficacy of gamma-irradiated Schistosoma japonicum cercariae with the defined antigen Sj62(IrV-5) in pigs. Vet Parasitol. 2001; 100(1-2):51-62. DOI: 10.1016/s0304-4017(01)00483-6. View

Pearce E, Caspar P, Grzych J, Lewis F, Sher A . Downregulation of Th1 cytokine production accompanies induction of Th2 responses by a parasitic helminth, Schistosoma mansoni. J Exp Med. 1991; 173(1):159-66. PMC: 2118762. DOI: 10.1084/jem.173.1.159. View

Poulin G, Nandakumar R, Ahringer J . Genome-wide RNAi screens in Caenorhabditis elegans: impact on cancer research. Oncogene. 2004; 23(51):8340-5. DOI: 10.1038/sj.onc.1208010. View

Wu Z, Lu Z, Yu X . Development of a vaccine against Schistosoma japonicum in China: a review. Acta Trop. 2005; 96(2-3):106-16. DOI: 10.1016/j.actatropica.2005.08.005. View

10.

Tang L, Zhou Z, Chen Y, Luo Y, Wang L, Chen L . Vaccination of goats with 31 kDa and 32 kDa Schistosoma japonicum antigens by DNA priming and protein boosting. Cell Mol Immunol. 2007; 4(2):153-6. View

11.

Poulain-Godefroy O, Menozzi F, Alonso S, Vendeville C, Capron A, Locht C . Adjuvant activity of free Bordetella pertussis filamentous haemagglutinin delivered by mucosal routes. Scand J Immunol. 2003; 58(5):503-10. DOI: 10.1046/j.1365-3083.2003.01336.x. View

12.

Wilson M, Mentink-Kane M, Pesce J, Ramalingam T, Thompson R, Wynn T . Immunopathology of schistosomiasis. Immunol Cell Biol. 2006; 85(2):148-54. PMC: 3437548. DOI: 10.1038/sj.icb.7100014. View

13.

Kariuki T, Farah I . Resistance to re-infection after exposure to normal and attenuated schistosome parasites in the baboon model. Parasite Immunol. 2005; 27(7-8):281-8. DOI: 10.1111/j.1365-3024.2005.00783.x. View

14.

Cardoso F, Pacifico R, Mortara R, Oliveira S . Human antibody responses of patients living in endemic areas for schistosomiasis to the tegumental protein Sm29 identified through genomic studies. Clin Exp Immunol. 2006; 144(3):382-91. PMC: 1941986. DOI: 10.1111/j.1365-2249.2006.03081.x. View

15.

Brave A, Ljungberg K, Wahren B, Liu M . Vaccine delivery methods using viral vectors. Mol Pharm. 2007; 4(1):18-32. DOI: 10.1021/mp060098+. View

16.

Simpson A, Alves-Oliveira L, Carvalho-Queiroz C, Silveira A, Viana I, Cunha-Melo J . Evidence that cellular immune responses to soluble and membrane associated antigens are independently regulated during human schistosomiasis mansoni. Parasite Immunol. 1996; 18(2):53-63. DOI: 10.1046/j.1365-3024.1996.d01-49.x. View

17.

Walter K, Fulford A, McBeath R, Joseph S, Jones F, Kariuki H . Increased human IgE induced by killing Schistosoma mansoni in vivo is associated with pretreatment Th2 cytokine responsiveness to worm antigens. J Immunol. 2006; 177(8):5490-8. DOI: 10.4049/jimmunol.177.8.5490. View

18.

Hewitson J, Hamblin P, Mountford A . In the absence of CD154, administration of interleukin-12 restores Th1 responses but not protective immunity to Schistosoma mansoni. Infect Immun. 2007; 75(7):3539-47. PMC: 1932915. DOI: 10.1128/IAI.00252-07. View

19.

Layland L, Wagner H, Prazeres Da Costa C . Lack of antigen-specific Th1 response alters granuloma formation and composition in Schistosoma mansoni-infected MyD88-/- mice. Eur J Immunol. 2005; 35(11):3248-57. DOI: 10.1002/eji.200526273. View

20.

Yuan H, You-En S, Long-jiang Y, Xiao-Hua Z, Liu-Zhe L, Cash M . Studies on the protective immunity of Schistosoma japonicum bivalent DNA vaccine encoding Sj23 and Sj14. Exp Parasitol. 2006; 115(4):379-86. DOI: 10.1016/j.exppara.2006.09.022. View